Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization
American Journal of Ophthalmology, Volume 146, No. 3, Year 2008
Notification
URL copied to clipboard!
Description
Purpose: To assess the role of bevacizumab in inflammatory ocular neovascularization. Design: Retrospective, multicenter, consecutive case series of inflammatory ocular neovascularization. Methods: Patients with inflammatory ocular neovascularization of varying causes for whom standard therapy failed were treated with intravitreal injection of bevacizumab. Main outcome measures included improvement of best-corrected visual acuity (BCVA) expressed in logarithm of minimum angle of resolution units, response of inflammatory ocular neovascularization by funduscopy and angiography, and decrease in central foveal thickness as measured by optical coherence tomography at the three-month follow-up. Results: At the three-month follow-up, 84 eyes of 79 patients had been treated with a mean of 1.3 injections (range, one to three). Thirty-four eyes showed juxtafoveal choroidal neovascularization (CNV), 34 eyes showed subfoveal CNV, eight eyes showed peripapillary CNV, and 11 eyes showed neovascularization of the disc (NVD) or neovascularization elsewhere (NVE). BCVA improved 2.4 lines from 0.68 (6/28 or 20/94) to 0.44 (6/17 or 20/55) (P < .001). BCVA improved by one to three lines in 34.5% of the eyes, by four to six lines in 16.7% of the eyes, and by more than six lines in 14.2% of the eyes. Function was unchanged in 23.8% of the eyes. BCVA worsened in 10.7% (zero to three lines in 7.1%, more than four lines in 3.6%). Central foveal thickness decreased from baseline 346 to 252 μm (P < .001). For CNV, 32 eyes (43.2%) had complete regression after the injection, 27 (36.5%) had partial regression, five (6.8%) had no response, and 10 eyes (13.5%) were not evaluated by the contributors. For NVD or NVE, seven eyes (63.6%) had complete regression of new vessels and four eyes (36.4%) had partial regression after the injection. Conclusions: Intravitreal bevacizumab led to short-term significant visual improvement and regression of inflammatory ocular neovascularization in a wide variety of inflammatory ocular diseases. © 2008 Elsevier Inc. All rights reserved.
Authors & Co-Authors
Mansour, Ahmad M.
Lebanon, Beirut
American University of Beirut
Mackensen, Friederike
Germany, Heidelberg
Universität Heidelberg
Arévalo, José Fernando
Venezuela, Merida
Universidad de Los Andes, Merida
Ziemssen, Focke
Germany, Tubingen
Eberhard Karls Universität Tübingen
Mahendradas, Padmamalini
India, Bangalore
Tuebingen Bevacizumab Study Group
Mehio-Sibai, Abla
Lebanon, Beirut
American University of Beirut
Hrisomalos, Nicholas
United States, Indianapolis
Indiana University-purdue University Indianapolis
Lai, Timothy Y.Y.
Hong Kong, Hong Kong
Chinese University of Hong Kong
Dodwell, David
United States, Springfield
Springfield Eye Clinic
Chan, Waiman
Hong Kong, Hong Kong
Chinese University of Hong Kong
Ness, Thomas
Germany, Freiburg Im Breisgau
Universitätsklinikum Freiburg
Banker, Alay
India, Ahmedabad
Laser Centre
Pai, Sivakami A.
India, Bangalore
Tuebingen Bevacizumab Study Group
Berrocal, María H.
Puerto Rico, San Juan
Universidad de Puerto Rico
Tohme, Rania A.
India, Bangalore
Tuebingen Bevacizumab Study Group
Heiligenhaus, Arnd
Germany, Munster
St. Franziskus-hospital Münster
Bashshur, Ziad F.
Lebanon, Beirut
American University of Beirut
Khairallah, Moncef
Tunisia, Monastir
Chu Fattouma-bourguiba
Salem, Khalil M.
Lebanon, Beirut
American University of Beirut
Hrisomalos, Frank N.
United States, Indianapolis
Indiana University-purdue University Indianapolis
Wood, Matthew H.
United States, Lincoln
Surgical Associates of Lincoln, pc
Heriot, Wilson
Australia, Malvern
Cabrini Health
Adán, Alfredo Manuel
Spain, Barcelona
Universitat de Barcelona
Kumar, Atul
India, New Delhi
Dr. Rajendra Prasad Centre for Ophthalmic Sciences
Lim, Lyndell L.
Australia, Melbourne
University of Melbourne
Hall, Anthony
Australia, Malvern
Cabrini Health
Australia, Melbourne
The Alfred
Becker, Matthias
Germany, Heidelberg
Universität Heidelberg
Statistics
Citations: 68
Authors: 27
Affiliations: 19
Identifiers
Doi:
10.1016/j.ajo.2008.05.024
ISSN:
00029394
Study Design
Cohort Study